4D Molecular Therapeutics Inc — Balance Sheet (NASDAQ:FDMT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 288.33 M353.49 M261.85 M339.89 M560.38 M566.71 M Total liabilities 31.94 M34.38 M30.51 M32.06 M49.78 M61.05 M Total equity 256.39 M319.11 M231.34 M307.83 M510.61 M505.66 M Total liabilities & shareholders' equities 288.33 M353.49 M261.85 M339.89 M560.38 M566.71 M Total debt —————— Net debt ——————

News

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aimei Health Technology (NASDAQ:AFJK), Aura Biosciences (NASDAQ:AURA)

Avago and Oracle among market cap stock movers on Wednesday

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential - Slideshow (NASDAQ:FDMT) 2025-12-17

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript